Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Drug Delivery
Pharma
Roche touts near-complete MS suppression for injectable Ocrevus
Roche's subcutaneous Ocrevus helped 97% of multiple sclerosis patients achieve no relapse up to 48 weeks of treatment.
Angus Liu
Apr 17, 2024 11:00am
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
Apr 1, 2024 10:45am
Appeals court backs Regeneron's antitrust suit against Novartis
Mar 19, 2024 10:40am
Formosa snags FDA nod for reformulation of decades-old steroid
Mar 5, 2024 11:36am
Grifols preps blood clot treatment approval push after ph. 3 win
Feb 14, 2024 9:10am
BMS touts latest Opdivo data as I-O battle heads to new front
Jan 29, 2024 8:45am